Dose-dependent Effects of Oxytocin on the Amygdala and Reward System
Dose-dependent Effects of Oxytocin on the Amygdala and Reward System Vary Between Women and Men
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bonn, Germany, 53105
- Department of Psychiatry, University of Bonn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy female volunteers
- Right-handed
- Non-smoker
Exclusion Criteria:
- Current psychiatric or physical illness
- Hormonal contraception
- Psychoactive medication
- MRI contraindication (e.g. metal in body, claustrophobia)
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Oxytocin & Placebo, 6 IU
Intranasal administration, 6 IU oxytocin nasal spray or placebo.
Imaging starting 45 min after nasal spray administration.
|
Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
The placebo nasal sprays contain identical ingredients except for the peptide itself.
|
|
Active Comparator: Oxytocin & Placebo, 12 IU
Intranasal administration,12 IU oxytocin nasal spray or placebo.
Imaging starting 45 min after nasal spray administration.
|
Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
The placebo nasal sprays contain identical ingredients except for the peptide itself.
|
|
Active Comparator: Oxytocin & Placebo, 24 IU
Intranasal administration, 24 IU oxytocin nasal spray or placebo.
Imaging starting 45 min after nasal spray administration.
|
Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
The placebo nasal sprays contain identical ingredients except for the peptide itself.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neural substrates of emotion processing, measured via blood-oxygen-level dependent signal in the amygdala
Time Frame: 45 min after nasal spray administration
|
Functional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli.
The investigators specifically plan to investigate amygdala responses to emotional faces, because previous studies found sex-specific effects of oxytocin on amygdala activation.
|
45 min after nasal spray administration
|
|
Neural substrates of emotion processing, measured via blood-oxygen-level dependent signal in striatal regions (putamen, nucleus accumbens, caudate, pallidum)
Time Frame: 45 min after nasal spray administration
|
Functional magnetic resonance imaging (fMRI) will be performed to measure blood-oxygen-level dependent signal in response to emotional face stimuli.
The investigators specifically plan to investigate striatal responses to emotional faces to explore sex-specific effects of OXT on reward-related brain activation.
|
45 min after nasal spray administration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: René Hurlemann, MD, PhD, University of Bonn
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PROXY2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.